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      Colorectal cancer (CRC) is a global health problem.  In the United States, 
approximately 1 in 20 people will be diagnosed with CRC in their lifetime.  Typically, 
CRC is associated with inflammation.  Many factors influence CRC risk and development, 
most of which work through an inflammation connection.  While genetics can play a role 
in CRC risk, lifestyle factors that promote inflammation seem to largely influence CRC 
risk and development.  CRC inflammation factors mainly result from diet.  Cancer is 
consistently linked with inflammation.  Furthermore, increased systemic inflammation, as 
evaluated by chemokines, is consistently related to increased recurrence and decreased 
survival of CRC.  The purpose of this study is to assess sugar intake (specifically fructose, 
glucose, and sucrose) and its association with systemic inflammatory and angiogenesis 
markers in colorectal cancer patients.  ColoCare is a multicenter, international prospective 
cohort study with the goal of following over 5,000 patients who are newly diagnosed with 
CRC.  The study employs longitudinal assessment of biomarkers and health behaviors and 
repeated sampling at multiple time points of multiple biological specimens.  Specifically, 
the blood samples analyzed for this paper were from baseline blood samples collected pre- 
or peri-surgery.  At 6-months post-baseline, the EPIC food frequency questionnaire (FFQ) 
was administered.  This food frequency questionnaire covered the year prior, which means 
it assessed diet 6-months pre-diagnosis and the 6-months post-diagnosis.  To evaluate 
		
inflammation, we measured blood plasma inflammatory markers associated with cancer: 
C-reactive protein (CRP), serum amyloid A (SAA), intercellular adhesion molecule 
(SICAM), vascular cell adhesion molecule (SVCAM), interleukin-6 (IL-6), interleukin-8 
(IL-8), monocyte chemoattractant protein 1 (MCP1), and tumor necrosis factor α (TNFα) 
and blood plasma angiogenesis markers associated with cancer: vascular endothelial 
growth factor-a (VEGFA) and vascular endothelial growth factor–d (VEGFD).  Overall, 
no significant associations between sugar intake and systemic inflammatory and 
angiogenesis markers were observed. With body mass index (BMI(kg/m2)) stratification, 
there were significant inverse correlations between sugar intake and VEGFD and MCP1 
levels in those with a BMI < 25kg/m2 and a significant positive association between sugar 
intake and SVCAM in those with a BMI ≥ 25kg/m2, as measured by Pearson’s correlation.  
Additionally, there was a significant association between higher sugar intake, as a 
percentage of total kcals, and lower VEGFD levels in those with a BMI < 25kg/m2, as 
measured by Spearman’s correlation.  These results are contrary to the popular slogan 
“sugar feeds cancer.”  Many cancer patients wish to use diet to improve their prognosis, 
yet research is lacking in this field.  This study helps to improve the understanding between 
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	BACKGROUND AND LITERATURE REVIEW 
 
1.1 Colorectal Cancer Prevalence and Incidence 
Colorectal cancer (CRC) is a global health problem.  In the United States, 
approximately 1 in 20 people will be diagnosed with CRC in their lifetime.1  CRC is the 
fourth most common cancer in the United States, comprising 8.0% of all new cancer cases.1  
Despite improving survival rates, CRC is the second leading cause of cancer-related 
mortality in the United States.1, 8  In Europe, CRC is the second most common cancer and 
the second most common cause of cancer-related deaths.9  Additionally, CRC incidence 
continues to increase in both men and women, with a high variation in incidence rates 
across Europe.10  Globally, cancer rates continue to rise, with unequal distributions of 
diagnosis and mortality between developed and less developed nations.11, 12  Overall, these 
statistics highlight the burden that CRC exerts on society worldwide.   
 
1.2.1 Mechanisms of CRC Development 
CRC is a slow-growing, heterogeneous oncological disease that develops via several 
pathways.13, 14  For all pathways, genetic instability results from an accumulation of genetic 
and epigenetic molecular alterations.15  Alterations occur in a stepwise fashion wherein 
normal mucosal cells transform into malignant cells.16  Most CRC cancers originate as 
polyps which progress to adenomatous polyps and finally to malignant polyps, though only 




develop sporadically, with only 25% of cases resulting from hereditary mutations.17  Three 
main pathways to CRC exist: chromosomal instability, microsatellite instability, and CpG 
island methylator phenotype.13, 15, 19-21  Chromosomal instability refers to the development 
of adenomas, and consequently cancer, through a series of progressive mutations of several 
genes, such as K-ras, APC, and p53.22, 23  Chromosomal instability is the most common 
pathway to CRC and is often termed the “adenoma-carcinoma sequence.”24     
Portions of DNA contain “motifs” of repeated tracts of nucleotides, such as the 
sequence TATATATATA; “microsatellites” is the term for motifs that are repeated three 
to hundreds of times.22  Microsatellite instability occurs when mismatch repair genes are 
inactivated and there is a change in the number of repeated DNA nucleotides (“motifs”) in 
a microsatellite.22  Finally, CpG islands are regions of DNA where there is a high frequency 
of cytosine nucleotides followed by guanine nucleotides.  The cytosine nucleotides can be 
methylated or unmethylated, either of which can change the  expression of a gene.25  Most 
often, the cytosine nucleotide lacks methylation.25  The CpG methylator phenotype 
pathway involves hypermethylation of CpG islands, which silences tumor suppressor 
genes.  To note, all three of these pathways can occur in both sporadic and hereditary 
CRC.20, 22 
 
1.2.2 CRC Risk Factors and the Role of Inflammation 
Typically, CRC is associated with inflammation.  Many factors influence CRC risk and 
development, most of which work through an inflammation connection.2  While genetics 
can play a role in CRC risk, lifestyle factors that promote inflammation seem to largely 




Under normal conditions, colonocytes utilize short chain fatty acids as the main source of 
fuel.3  Short chain fatty acids result from the fermentation of dietary fibers.  Diets low in 
dietary fiber decrease the preferred fuel source for colonocytes and thereby negatively alter 
colonocyte metabolism.3  High levels of nitrogenous compounds within the colon induce 
inflammation and mucosal damage in the colon, thereby resulting in a high-risk luminal 
environment.3   Poor diet, as defined by the low consumption of fruits, vegetables, whole 
grains, legumes, and high intake of processed grains and meat, can directly and indirectly 
affect inflammation in the colon and rectum.  Directly, red and processed meat and animal 
fats can trigger an inflammatory response via the formation of N-nitroso compounds and 
expansion of pro-inflammatory microorganisms.3  Indirectly, poor diet resulting in weight 
gain and obesity can favor a systemic pro-inflammatory state.3, 26  In addition, tissue injury, 
as a result of mechanical, infectious, or chemical damage, causes a chronic inflammation 
response.3  This chronic inflammatory response confers an oxidative and anaerobic 
microenvironment.3 This microenvironment is associated with DNA damage and altered 
cellular mechanisms, ultimately resulting in a failure of normal mucosa repair and 
renewal.19  Additionally, chronic inflammation seems to increase cancer predisposition27 
through activating signaling pathways that directly or indirectly modulate the epigenome, 
which then affects genes in GI homeostasis and repair.  
  
1.2.3 The Role of Epigenetics in CRC Development 
Epigenetic modifications are changes in gene expression not related to changes in 
primary gene nucleotide sequence.  These modifications include DNA methylation, histone 




and diversity.28, 29  CRC occurrence is more often due to sporadic changes rather than 
genetic alterations.  These sporadic changes seem to largely result from epigenetic 
modifications.28   
Recent research suggests diet can drive epigenetic changes; this provides a molecular 
mechanism that may explain, in part, the connection between diet and CRC.27, 30    Diet can 
render protective or inducive epigenetic modifications related to CRC.30  Within CRC 
specifically, different epigenetic modifications have been found on different genes.  
Broadly speaking, epigenetic modifications contribute, determine, and affect CRC 
initiation, progression, and recurrence.31  Fortunately, epigenetic modifications are 
reversible, so dietary changes may have a considerable impact on CRC occurrence and 
progression.  
 
1.2.4 Markers to Measure Systemic Inflammation  
Hanahan and Weinberg first proposed the hallmarks of cancer as the following: 
sustaining proliferative signaling, evading growth suppressors, resisting cell death, 
enabling replicative immortality, inducing angiogenesis, and activating invasion and 
metastasis.32  Colotta suggested inflammation is the seventh hallmark of cancer.33  Cancer 
is consistently linked with inflammation.4  Furthermore, increased systemic inflammation, 
as evaluated by chemokines, is consistently related to increased recurrence and decreased 
survival of CRC.4-7  The mechanism behind increased inflammation and increased 
recurrence and decreased survival of cancer is thought to relate to the tumor-promoting 
effects of inflammation in the tumor microenvironment.4 Inflammation aids in proliferation 




immune responses.4     
Chemokines fall in the family of chemotactic cytokines.4  Cancer-related inflammation 
is largely regulated by chemokines and these chemokines regulate tumor growth, 
angiogenesis, and metastasis.34  Broadly, across many cancers, CRP, TNFα, MCP1, IL-6, 
and IL-8 are connected with inflammation34, 35; ICAM and VCAM are associated with 
inflammation and cancer cell invasion35; VEGFA and VEGFD are correlated with cancer 
cell angiogenesis.34, 35  In CRC specifically, IL-6 and TNFα have been implicated in the 
promotion of tumor growth, invasion, and metastasis.5  In a cohort of stage IV CRC 
patients, Sharma found a positive correlation between IL-8 and VEGF with 
carcinoembryonic antigen, which is often used to track cancer growth.5  Additionally, Di 
Caro reported high VEGF levels associated with increased risk of CRC recurrence and 
worsened survival among stage 0-IV CRC patients.6   
 
1.3 Diet and CRC 
1.3.1 Epidemiological Evidence in Diet and CRC 
Diet and CRC Prevention and Progression 
Consistently, research demonstrates that the development of CRC cancer is more 
closely linked to diet than many other types of cancer.36  Most research agrees that 
consumption of fruits, vegetables, and whole grains has a protective effect in CRC 
prevention, whereas red meat and processed meat consumption has a detrimental effect.37-
39   Some evidence suggests that a high-fat diet can also promote CRC.3, 40  In contrast to 
prevention, there is limited definitive research on how diet influences the progression of 




spreading throughout the body.  Regarding diet and CRC progression, the conclusions have 
been mixed.  In newly diagnosed CRC patients, Zhu et al. reported decreased disease-free 
survival in patients (n=529) who consumed a high processed meat dietary pattern and this 
effect was elevated in women.41  Additionally, no association between high sugar 
consumption or a prudent vegetable diet and mortality or recurrence was found.  While this 
study did assess diet and CRC progression, the food frequency questionnaire (FFQ) only 
reflected diet the year prior to diagnosis.41  In contrast, Fung et al. followed women 
(n=1201) who were diagnosed with CRC and evaluated diet through the Alternate Healthy 
Eating Index-2010 FFQ, which was administered 6-months after diagnosis.42  The 
Alternate Healthy Eating Index-2010 awards higher scores for increased intake of foods 
associated with lower risk of chronic disease, such as fruits, vegetables, whole grains, and 
omega-3 fatty acids.43  A higher Alternate Healthy Eating Index-2010 score was associated 
with lower overall mortality and when the components of the eating pattern were analyzed, 
decreased sugar-sweetened beverage and fruit juice consumption as well as decreased 
alcohol intake were specifically associated with lower overall mortality.  Interestingly, no 
association with overall or CRC-specific mortality was found with the Western dietary 
pattern, which is characterized by higher intakes of red and processed meats, refined grains, 
sweets and desserts, and high fat dairy products.42, 44  This pattern was also found in a study 
by Meyerhardt et al. that assessed dietary glycemic load and cancer recurrence among 
stage-III CRC patients45: a higher glycemic load and total carbohydrate intake were 
significantly associated with decreased disease-free, recurrence-free, and overall survival.  
Interestingly, the relationship between dietary glycemic load and disease-free survival was 




the influence of glycemic load on survival was modified by body mass index 
(BMI(kg/m2)): overweight or obese participants with a high glycemic load had a 
significantly worsened disease-free survival, as compared to healthy weight participants.45 
Fuchs et al. also found this progressive association between increased BMI(kg/m2) and 
increased cancer recurrence among patients consuming sugar-sweetened beverages.46  
Lastly, Meyerhardt et al. noted glycemic load had a greater adverse influence on disease-
free survival than the level of Western diet pattern.45  Although available evidence at this 
point is limited, the majority of the evidence implicates dietary sugar as playing an adverse 
role in CRC progression and survival. The mechanisms through which sugar impacts CRC 
progression and outcome remain to be determined.   
 
1.4 Sugar and Cancer 
1.4.1 Definition of Sugars 
The term sugar generally encompasses mono- and di-saccharides.  The three mono-
saccharides are glucose, fructose, and galactose.  Sucrose, lactose, and maltose are the three 
di-saccharides.  The most predominant sugars in the human diet are glucose, fructose, 
lactose, and sucrose.47  Glucose is found in its polymer form within starch-rich foods such 
as grains.47  Fructose is found naturally within fruit.48  Fructose and glucose bond to form 
sucrose.47  Sucrose is commonly referred to as “table sugar.”  Any prepared food product 
with “sugar” in the ingredients contains sucrose.  Currently, a main source of sugar in 
human diets is high fructose corn syrup (commonly referred to as HFCS).48  HFCS  is a 
corn-derived sweetener developed in the 1960s.48  Typically, HFCS is a mixture of 55% 




approximately 19 grams of total sugar, with 11 grams as fructose.49  A medium apple also 
contains 4.4 grams of fiber, which slows the rise in blood sugar.47, 49  By comparison, a 12 
oz can of Coke contains 39 grams of sugar in the form of HFCS, and no fiber.50  Thus, one 
12 oz can of Coke contains 21.45 grams of free fructose with no fiber to blunt the resulting 
rise in blood sugar.   
Within the human body, only mono-saccharides are absorbed by intestinal mucosal 
cells utilizing different transporters, both active and facilitative, for each type.  Once 
absorbed, fructose and galactose must pass through the portal vein to the liver for 
processing before reaching the general blood stream, whereas glucose can be absorbed 
throughout the body and thus does not require prior processing in the liver.47  Fructose is 
of interest since its metabolism in the liver bypasses a regulatory step, unlike glucose and 
galactose.48  By bypassing phosphofructokinase, a regulatory enzyme in glycolysis, high 
intake of fructose can result in dyslipidemia.48  Fructose metabolism also occurs 
independently of insulin, unlike glucose.   Additionally, fructose seems to induce hepatic 
and extrahepatic insulin resistance.51  These metabolic findings support the role of fructose 
in obesity, blood lipid disorders, cardiovascular disease, and metabolic syndrome.48   
 
1.4.2 Potential Role of Sugar in Cancer 
The FDA defines “added sugar” as sugars that are added during the processing of foods 
or are packaged as “sugar.”52  Considerable epidemiological evidence associates added 
sugar with cardiovascular risk,51, 53, 54 type II diabetes,55 unfavorable lipid levels, insulin 
resistance, fatty liver, and metabolic syndrome.51, 56  Currently, there is increasing evidence 




Specifically, it appears sugar can help influence the cellular events within a tumor and 
affect the tumor microenvironment.57  Furthermore, the type of sugar, fructose versus 
glucose, is a consideration. Fructose, in particular, increases reactive oxygen species, 
inflammation, and cytokines.57  Research demonstrates there are fundamental differences 
in the way cancer cells utilize sugars, as compared to non-cancer cells.57  For example, 
Zamora-León found the fructose transporter GLUT5 highly expressed in human breast 
cancer cells, but absent in normal human breast tissue.58  However, sugar may confer 
different cancer risks depending on the tissue.57  Overall, sugar appears to promote 
inflammation in a broad systemic context and specific tumor cell context.57 
Broadly, it appears that some cancers are promoted by hyperinsulinemia and insulin 
resistance.26, 57  Both hyperinsulinemia and insulin resistance are influenced by obesity and 
added sugar in the diet.26, 57  The anabolic and anti-apoptotic effects of insulin are mediated 
by insulin binding to the insulin receptor or IGF-1 receptor.26  The IGF-1 receptor exerts 
proliferative and anti-apoptotic effects within a cell.  Increased insulin decreases IGFB-
1&2 levels, which causes an increase in free IGF-1 availability.26  Theoretically, chronic 
added sugar intake would result in overall increased insulin levels and thus tumor 
development would be promoted by the effects of elevated insulin and IGF-1.26  
Additionally, hyperglycemia alone leads to an increase in reactive oxygen species in B-
cells and accumulation of advanced glycation end-products, which further increases 
inflammation and formation of reactive oxygen species.  Collectively, these processes work 







Colorectal cancer patients with high added sugar (specifically fructose, glucose, and 
sucrose) intake, will have elevated circulating systemic inflammatory markers. 
 
1.6 Primary Aim and Secondary Aims 
1.6.1 Primary Aim 
1.  To assess the association between added sugar intake (specifically fructose, 
glucose, and sucrose) and circulating inflammatory markers in CRC patients.  
Potential confounders or effect modifiers include: age, gender, BMI(kg/m2), kcal 
intake, Type II Diabetes Mellitus (T2DM), FFQ version, and diet change.   
 
1.6.2 Secondary Aims 
2.   To assess the association between added sugar intake (specifically fructose, 
glucose, and sucrose) as a percentage of total kcal and circulating inflammatory 
markers in CRC patients.  Potential confounders or effect modifiers include: age, 
gender, BMI(kg/m2), kcal intake, T2DM, FFQ version, and diet change.   
3. To assess the association between sugar intake from sugar-sweetened beverages 
and circulating inflammatory markers in CRC patients.  Potential confounders or 
effect modifiers include: age, gender, BMI(kg/m2), kcal intake, T2DM, FFQ 









2.1 ColoCare Study Population 
ColoCare is a multicenter, international prospective cohort study with the goal of 
following over 5,000 patients who are newly diagnosed with CRC.  The seven study sites 
are the University Hospital in Heidelberg, Germany; the Fred Hutchinson Cancer Research 
Center in Seattle, WA; the Moffit Cancer Center in Tampa, FL; Cedars Mt. Sinai in Los 
Angeles, CA; Washington University School of Medicine in St. Louis, MO; the University 
of Tennessee in Memphis, TN; and the Huntsman Cancer Institute in Salt Lake City, UT.  
The overall aim is to develop evidence-based guidelines for physicians and patients to help 
increase survival of persons with CRC.  To develop these guidelines, the study employed 
longitudinal assessment of biomarkers and health behaviors and repeated sampling at 
multiple time points of multiple biological specimens [Figure 1].  This study protocol 
included extensive follow-up observations for 60 months, with approval under the IRB File 
310/2001-DACHS-ColoCare.  Eligibility criteria were as follows: new diagnosis of colon 
or rectal or rectosigmoidal carcinoma; staged 0/I-IV (according to the American Joint 
Committee on Cancer based on histopathological findings); between 18-80 years of age; 
and able to provide informed consent.  For this proposal specifically, the Heidelberg, 
Germany cohort data, with recruitment between February 2011 and October 2014, were 
analyzed.  Specifically, patients with an available 6-month FFQ and baseline blood samples 





2.2 ColoCare Study Design 
The design of the study is summarized in Figure 1.  Participants were recruited at 
diagnosis of CRC (referred to as “baseline”) and followed for 60 months.  At baseline, pre-
surgery blood was collected along with urine, stool, saliva, tumor, normal mucosa, and 
adipose tissue samples.  The blood, urine, stool, and saliva specimen collections were 
repeated at 6, 12, and 24 months.  Questionnaires covering health behaviors, symptoms, 
and quality of life were administered at baseline.  These questionnaires were repeated at 3, 
6, 12, 24, 36, 48, and 60 months.  At 6-months post-baseline, the EPIC FFQ were 
administered.  This FFQ covered the year prior, which means it assessed the 6-months pre-




were from baseline blood samples collected pre- or peri-surgery.  Finally, chart abstraction 
on treatment toxicity and recurrence was performed for 60 months.  Outcome measures of 
the study (symptoms, quality of life, treatment toxicity, recurrence, and survival) were 
collected throughout the study.   
 
2.2.1 Blood Sample Collection and Processing 
Non-fasting blood samples were collected after diagnosis of colorectal cancer from 
ColoCare patients in Heidelberg, Germany.  Blood samples were recollected at 6-, 12-, and 
24-months post-baseline.  As stated above, the blood samples used for this paper were the 
6-month samples.  Serum was extracted from the whole blood within 4 hours of the blood 
draw.  Samples were then frozen at -80°C and shipped, on dry ice, to the Huntsman Cancer 
Institute (Salt Lake City, UT) for storage at -80°C until analysis.   
 
2.2.2 Biomarkers of Inflammation and Angiogenesis  
      To evaluate inflammation, we measured blood plasma inflammatory markers 
associated with cancer: C-reactive protein (CRP), serum amyloid A (SAA), intercellular 
adhesion molecule (SICAM), vascular cell adhesion molecule (SVCAM), interleukin-6 
(IL-6), interleukin-8 (IL-8), monocyte chemoattractant protein 1 (MCP1), and tumor 
necrosis factor α (TNFα) and blood plasma angiogenesis markers associated with cancer: 







2.2.3 Laboratory Methods (Meso Scale Discovery) 
Serum samples were brought from -80°C to room temperature and pipetted into assay 
plates.  A Meso Scale Discovery (MSD) sector 2400A (Meso Scale Diagnostics, Rockville, 
MD) was used to analyze the inflammation markers.  The markers were split between plates 
as follows: IL-6, IL-8, MCP-1, and TNFα on a U-Plex plate; CRP, SAA, sICAM-1, and 
sVCAM-1 on a V-Plex Vascular Injury Plate; and VEGF-A and VEGF-D on a V-Plex 
Angiogenesis Panel 1 plate.  Serum samples on the V-Plex plates had not been freeze-
thawed.  U-Plex plate serum was freeze-thawed twice.  Freeze-thawing could have affected 
analyte levels; however, a literature review suggested the effect as negligible.  Serum 
samples were all run in duplicate with three controls on each plate.  The order of the 
samples was blinded and decoded after each assay run. The overall inter-plate coefficient 
of variability was 9.9% and intra-plate coefficient of variability was 4.6%.   
 
2.2.4 Food Frequency Questionnaire 
ColoCare Heidelberg utilizes the validated 148-item European Prospective 
Investigation into Cancer and Nutrition (EPIC) FFQ Potsdam, which is semi-quantitative 
and self-administered59, 60.  The EPIC FFQ reflects the frequency of food intakes for all 
main food groups during the past 12 months.  At the inception of the ColoCare project, the 
first version of the EPIC-FFQ was used; the second version (FFQ2) was introduced at the 
beginning of 2014.  The second version includes more food options, regrouped food in 
some categories, added questions about general diet, and decreased monitoring supplement 
use from two years prior to one year prior.  For this paper, FFQ data output spanned both 




A food database was used to evaluate the nutrients in each food item.  Utilizing the 
European Prospective Investigation into Cancer and Nutrition (EPIC)-Soft software, food 
items were grouped into 80 classes.61  According to the classification of the EPIC project, 
the 80 food classes were then assigned into 25 food groups based on nutrients or culinary 
usage.  The food groups included four groups of vegetable intake, three groups of meat 
intake, one group of fruit and fish intake, four groups of fat intake, and twelve other food 
groups.  Intake frequency was evaluated by a scale with values ranging from “never”, “one 
time per month or less”, “two to three times per month”, “one to two times per week”, to 
“three times per week or more.”  Portion sizes were defined by household measures.  The 
food group data were combined with consumption frequency and typical portion sizes to 
yield estimates of kilocalorie (kcal) consumption and grams per day of fat, protein, 
carbohydrates, fiber, sugar, and micronutrients. 
 
2.3 Statistical Methods 
      All data were analyzed in SAS (Version 9.4, SAS, Cary, NC).  Descriptive statistics 
were used to summarize the distributions of the demographic clinical characteristics, 
nutritional intakes, and systemic inflammatory markers.   
      First, overall associations between sugar intake (both in terms of total kcal/day and 
percentage of kcal/day) and systemic inflammatory markers were evaluated.  Additionally, 
correlation between BMI(kg/m2) and sugar intake was assessed.  Next, the data were 
stratified based on BMI(kg/m2) (<25 and ≥25), age (<65 and ≥65), and sex.  We then tested 
for correlation, utilizing both Pearson and Spearman’s.  Any associations were assessed 




modification, based on the multiplicative rule.  This formal test determined what variables 
were effect modifiers and what variables were confounders.  
      Then we ran several multiple linear regressions, controlling for various confounders 
while stratifying by BMI(kg/m2).  And we adjusted for total kcals two ways: first viewing 
fructose, glucose, and sucrose as a percentage of total kcals and second, controlling for 
total kcals as a confounder. 
      The analyzed data were collected between February 2011 and October 2014.  The 
available sample size (ranging from only pre-surgical blood to both pre- and peri-surgical 
blood) was as follows: CRP: 138-153, SAA: 129-142, SICAM: 141-179, SVCAM: 141-
157, VEGFA: 144-160, VEGFD: 144-161, IL-6: 150-169, IL-8: 150-169, MCP1: 150-169, 
and TNFα: 150-169. 
      A simple power analysis for a correlation between two variables, such as sugar level 
and an inflammation variable, indicated that correlations between 0.19 to 0.28 would have 
power levels from 0.7 to 0.9 for sample size ranging from 129-168 when using a 














3.1 Descriptive Statistics 
       Following previous research,62-65 any patient with an estimated total kcal intake 
<600kcal/day and > 4000kcal/day was excluded from the final analysis (n=6).  Further, 
one patient was excluded due to a data entry error, with a recorded intake of soda beyond 
allowable by the FFQ.  Next, patients who were in an acute inflammatory reaction were 
excluded.  Previous research utilized CRP outliers to detect an acute inflammatory 
reaction.66  The following equations were used to determine CRP outliers above the 95th 
percentile: Caucasian or Hispanic men: age/5 = URL CRP in mg/L; Caucasian or Hispanic 
women: age/5 + 6 = URL CRP in mg/L; Black men: age/3 = URL CRP in mg/L; Black 
women: age/5 + 10 = URL CRP in mg/L.  These equations resulted in an age-specific upper 
reference limit (URL) of CRP. This URL CRP was multiplied by 1.5 to yield 
approximately the 97th percentile of CRP.  Any patient with CRP >50mg/L was dropped 
from all inflammatory markers except for VEGFD and VEGFA, which are angiogenesis 
markers (n=4).  Any patient with a high CRP, as defined by 1.5 times the URL CRP, was 
removed from CRP and SAA analyses (n=11).  Any patient with a CRP >1.5 times the 
URL CRP and a BMI of > 27.5 kg/m2 was excluded from CRP and SAA analyses, due to 
overweightness explaining inflammation (n=1).   
      Study participants were both female and male. Participant ages ranged from 27 to 87 




a mean BMI of 26.3 kg/m2.  The cohort contained patients with all stages of CRC; however, 
the majority of patients were in Stage II and III.  Among cohort patients, the site of cancer 
was split nearly evenly between the colon and rectum.  A descriptive table of the 
characteristics of the cohort is displayed in Table 1.   
      Once outliers were dropped, all sugar distributions normalized.  The distribution of 
intake, in kcals/day, of sucrose, glucose, and fructose varied greatly.  As a percentage of 
total kcals, sucrose, glucose, and fructose intake ranged from 0-20%, 0-10%, and 0-20%, 
respectively.  Total kcal intake displayed a normal distribution, with a mean of 2300 
kcal/day.   
      The main contributors of sucrose in the diet were the “sugar and confectionary” food 
group, “dairy” food group, and “fruit” food group, respectively; these groups contributed 
68% of total sucrose intake.  The main contributors of glucose in the diet were the “fruit” 
food group, “non-alcoholic beverages” food group, and “sugar and confectionary” food 
group, respectively; these groups contributed 71% of total glucose intake.  Finally, the main 
contributors of fructose in the diet were the “non-alcoholic beverages” food group, “fruit” 
food group, and “sugar and confectionary” food group, respectively, as 80% of total 
fructose intake. 
      Many of the systemic inflammatory markers exhibited long tails, as was expected.  
Once the inflammatory markers were log transformed, distribution normalized.  The means 










Table 1: Descriptive statistics of study population (N=191) 
Demographics and clinical characteristics 
Variable n (%) 
Female 69 (36.1%) 
Male 122 (63.9%) 
Age (y)  
<50 20 (10.5%) 
50-60 55 (28.8%) 
>60 116 (60.7%) 
BMI (kg/m2) 
BMI <18.5 3 (1.6%) 
BMI 18.5-24.9 60 (31.6%) 
BMI 25.0-29.9 94 (49.5%) 
BMI ≥ 30 33 (17.4%) 
BMI unknown 1 
Stage of CRC  
Stage 0 17 (8.9%) 
Stage I 35 (18.3%) 
Stage II 64 (33.5%) 
Stage III 49 (25.7%) 
Stage IV 26 (13.6%) 
Site of CRC 
Colon 86 (45.0%) 
Rectosigmoid 13 (6.8%) 
Rectum 92 (48.2%) 
Nutritional Intakes Mean ± S.D. 
Sugar intake in kcals/day  
Sucrose  255.8 ± 120.17 
Glucose  85.0 ± 51.90 
Fructose  109.6 ± 65.99 
Sugar intake in percentage of kcals/day 
Sucrose/Total Kcals  10% ± 3% 
Glucose/Total Kcals  0% ±  2% 
Fructose/Total Kcals  0% ±  2% 
Total kcals/day 






Table 2: Descriptive statistics of study population (N=191) 
Biomarkers of inflammation and angiogenesis  
Biomarker (pg/ml) mean±S.D. 
CRP 4.4 ± 4 
SAA 9.2 ± 15 
SICAM 0.4 ± 0.16 
SVCAM 0.6 ± 0.19 
VEGFA 796.2 ± 589 
VEGFD 856.9 ± 303 
IL6 1.8 ± 10 
IL8 26.9 ± 90 
MCP1 184.4 ± 108 





























      Overall, no significant associations between sugar intake and systemic inflammatory 
and angiogenesis markers were observed.  Notably, there was no correlation between sugar 
intake and BMI (kg/m2).  With BMI(kg/m2) stratified, there were significant inverse 
correlations between sugar intake and VEGFD and MCP1 levels in those with a BMI < 
25kg/m2 and a significant positive association between sugar intake and SVCAM in those 
with a BMI ≥ 25kg/m2, as measured by Pearson’s correlation [Table 3].  With visual 
assessment, the associations reflected clear slopes and were not impacted by outliers 
[Figures 2 & 3].  When adjusted for age and gender, the significant associations between 
sugar intake and VEGFD and MCP1 were still present in those with a BMI < 25kg/m2, as 
was SVCAM in those with a BMI ≥ 25kg/m2 [Table 4].   
      Additionally, there were significant associations between sugar intake and VEGFD, 
MCP1, and IL-6 levels in those with a BMI < 25kg/m2 and significant associations between 
sugar intake and VEGFA and MCP1 in those with a BMI ≥ 25kg/m2, as measured by 
Spearman’s correlation [Table 5].  Furthermore, when adjusted for age and gender, the 
significance as measured by Spearman’s correlations between sugar intake and VEGFD, 
MCP1, and IL-6 was still present in those with a BMI < 25kg/m2, as was MCP1 in those 
with a BMI ≥ 25kg/m2 [Table 6].   
      Through testing for effect modification, we determined BMI(kg/m2) to be an effect 
modifier and age and gender to be confounders.  Next, we adjusted for total kcals two ways: 
1) first viewing fructose, glucose, and sucrose as a percentage of total kcals and 2) 










Table 3: Associations between sugar intake and systemic inflammatory and angiogenesis markers as measured by Pearson 
correlation and stratified by BMI(kg/m2) 














log2-CRP 0 (1.00) 0.05 (0.73) 0.06 (0.69) -0.06 (0.67) -0.02 (0.92) -0.03 (0.83) 
log2-SAA -0.14 (0.36) -0.13 (0.38) -0.11 (0.45) -0.09 (0.55) -0.11 (0.48) -0.08 (0.58) 
log2-SICAM -0.15 (0.30) -0.12 (0.42) -0.1 (0.49) -0.06 (0.68) -0.01 (0.95) 0 (0.98) 
log2-
SVCAM 
0.01 (0.92) -0.02 (0.90) 0.03 (0.85) 0.03 (0.86) -0.03 (0.81) 0.01 (0.95) 
log2-VEGFA 0.03 (0.85) -0.01 (0.94) -0.02 (0.89) 0.05 (0.72) -0.03 (0.82) -0.03 (0.84) 
log2-VEGFD -0.38 (0.00) * -0.42 (0.00) * -0.41 (0.00) * -0.25 (0.05) -0.27 (0.04) * -0.25 (0.05) 
log2-IL6 -0.11 (0.43) -0.22 (0.13) -0.18 (0.21) -0.11 (0.46) -0.23 (0.10) -0.19 (0.17) 
log2-IL8 -0.06 (0.64) -0.17 (0.19) -0.15 (0.26) 0.06 (0.66) -0.13 (0.31) -0.1 (0.47) 
log2-MCP1 -0.24 (0.07) -0.27 (0.04) * -0.27 (0.03) * -0.25 (0.05) -0.27 (0.04) * -0.29 (0.02) * 

















Table 3: Continued 














log2-CRP -0.03 (0.76) -0.04 (0.68) -0.12 (0.25) 0.17 (0.10) 0.08 (0.46) -0.03 (0.79) 
log2-SAA -0.2 (0.06) -0.16 (0.13) -0.13 (0.21) -0.08 (0.46) -0.09 (0.42) -0.06 (0.57) 
log2-SICAM -0.14 (0.17) -0.1 (0.34) -0.12 (0.24) -0.03 (0.75) -0.01 (0.89) -0.07 (0.53) 
log2-SVCAM -0.01 (0.94) 0.2 (0.05) * 0.16 (0.12) 0.02 (0.87) 0.27 (0.01) * 0.21 (0.04) * 
log2-VEGFA -0.18 (0.07) -0.14 (0.18) -0.11 (0.26) -0.06 (0.59) -0.06 (0.53) -0.03 (0.76) 
log2-VEGFD -0.05 (0.66) 0.08 (0.44) 0.08 (0.41) -0.06 (0.53) 0.1 (0.34) 0.11 (0.30) 
log2-IL6 0.06 (0.59) 0.17 (0.09) 0.09 (0.39) 0 (0.97) 0.12 (0.26) 0.03 (0.78) 
log2-IL8 0.01 (0.94) 0.12 (0.22) 0.08 (0.42) 0.02 (0.83) 0.13 (0.18) 0.08 (0.43) 
log2-MCP1 0.09 (0.36) 0.11 (0.27) 0.07 (0.44) 0.1 (0.32) 0.09 (0.33) 0.06 (0.53) 
log2-TNFa -0.09 (0.41) 0.03 (0.74) 0.03 (0.76) -0.05 (0.66) 0.08 (0.43) 0.07 (0.52) 































Table 4: Associations between sugar intake and systemic inflammatory and angiogenesis markers as measured by Pearson 
correlation, adjusted for age and gender and stratified by BMI(kg/m2) 














log2-CRP 0 (0.98) 0.06 (0.70) 0.06 (0.68) -0.06 (0.68) -0.01 (0.95) -0.03 (0.84) 
log2-SAA -0.13 (0.40) -0.12 (0.43) -0.11 (0.48) -0.09 (0.55) -0.1 (0.50) -0.09 (0.57) 
log2-SICAM -0.13 (0.37) -0.09 (0.55) -0.08 (0.56) -0.06 (0.69) 0.02 (0.92) 0.01 (0.95) 
log2-
SVCAM 
0.05 (0.74) 0.05 (0.74) 0.06 (0.70) 0.04 (0.76) 0.04 (0.81) 0.04 (0.79) 
log2-VEGFA 0.05 (0.71) 0.01 (0.95) -0.01 (0.96) 0.06 (0.67) -0.03 (0.82) -0.04 (0.76) 
log2-VEGFD -0.37 (0.00) * -0.42 (0.00) * -0.4 (0.00) * -0.26 (0.05) * -0.31 (0.02) * -0.29 (0.03) * 
log2-IL6 -0.12 (0.41) -0.2 (0.17) -0.18 (0.20) -0.08 (0.60) -0.19 (0.19) -0.18 (0.22) 
log2-IL8 -0.05 (0.72) -0.16 (0.22) -0.14 (0.29) 0.06 (0.64) -0.13 (0.33) -0.1 (0.43) 
log2-MCP1 -0.27 (0.04) * -0.26 (0.05) * -0.3 (0.02) * -0.23 (0.08) -0.22 (0.09) -0.27 (0.04) * 
















Table 4 Continued 














log2-CRP -0.01 (0.93) -0.03 (0.81) -0.12 (0.27) 0.18 (0.10) 0.08 (0.44) -0.04 (0.73) 
log2-SAA -0.17 (0.13) -0.13 (0.23) -0.13 (0.23) -0.08 (0.49) -0.08 (0.47) -0.08 (0.47) 
log2-SICAM -0.13 (0.21) -0.09 (0.40) -0.12 (0.26) -0.04 (0.73) -0.01 (0.89) -0.07 (0.50) 
log2-
SVCAM 
-0.01 (0.94) 0.20 (0.05) 0.16 (0.13) 0.03 (0.77) 0.29 (0.01) * 0.22 (0.04) * 
log2-
VEGFA 
-0.16 (0.12) -0.12 (0.24) -0.10 (0.35) -0.05 (0.61) -0.07 (0.51) -0.04 (0.73) 
log2-
VEGFD 
-0.08 (0.46) 0.05 (0.60) 0.05 (0.65) -0.06 (0.56) 0.10 (0.33) 0.09 (0.36) 
log2-IL6 0.04 (0.68) 0.17 (0.10) 0.09 (0.39) -0.01 (0.94) 0.12 (0.26) 0.04 (0.72) 
log2-IL8 0.01 (0.89) 0.12 (0.23) 0.07 (0.47) 0.03 (0.77) 0.13 (0.19) 0.07 (0.48) 
log2-MCP1 0.09 (0.37) 0.10 (0.30) 0.07 (0.48) 0.10 (0.30) 0.09 (0.33) 0.06 (0.54) 
log2-TNFa -0.07 (0.51) 0.03 (0.75) 0.02 (0.82) -0.04 (0.69) 0.07 (0.50) 0.05 (0.64) 













Table 5: Associations between sugar intake and systemic inflammatory and angiogenesis markers as measured by Spearman 
correlation and stratified by BMI(kg/m2) 














log2-CRP -0.01 (0.97) -0.06 (0.67) -0.03 (0.85) -0.06 (0.71) -0.11 (0.46) -0.11 (0.48) 
log2-SAA -0.13 (0.37) -0.16 (0.28) -0.15 (0.31) -0.03 (0.83) -0.07 (0.64) -0.08 (0.60) 
log2-SICAM -0.11 (0.46) -0.08 (0.55) -0.09 (0.53) -0.06 (0.66) -0.03 (0.86) -0.03 (0.83) 
log2-
SVCAM 
-0.08 (0.56) -0.09 (0.52) -0.09 (0.51) -0.07 (0.61) -0.09 (0.52) -0.05 (0.70) 
log2-VEGFA -0.13 (0.32) -0.21 (0.11) -0.22 (0.09) 0 (1.00) -0.05 (0.70) -0.05 (0.69) 
log2-VEGFD -0.3 (0.02) * -0.39 (0.00) * -0.38 (0.00) * -0.09 (0.51) -0.2 (0.13) -0.18 (0.18) 
log2-IL6 -0.28 (0.04) * -0.29 (0.04) * -0.25 (0.08) -0.13 (0.36) -0.12 (0.40) -0.11 (0.45) 
log2-IL8 -0.08 (0.52) -0.2 (0.12) -0.15 (0.26) 0.05 (0.73) -0.11 (0.40) -0.03 (0.83) 
log2-MCP1 -0.3 (0.02) * -0.38 (0.00) * -0.36 (0.00) * -0.34 (0.01) * -0.33 (0.01) * -0.32 (0.01) * 
















Table 5: Continued 














log2-CRP -0.02 (0.84) -0.08 (0.45) -0.14 (0.20) 0.19 (0.07) 0.13 (0.24) 0.03 (0.77) 
log2-SAA -0.18 (0.09) -0.09 (0.38) -0.08 (0.45) -0.1 (0.34) 0.01 (0.92) 0.01 (0.95) 
log2-SICAM -0.09 (0.37) -0.2 (0.05) -0.19 (0.06) 0.06 (0.55) -0.09 (0.38) -0.12 (0.27) 
log2-
SVCAM 
0.01 (0.94) 0.04 (0.70) 0.08 (0.45) 0.04 (0.69) 0.06 (0.53) 0.11 (0.28) 
log2-
VEGFA 
-0.21 (0.03) * -0.17 (0.10) -0.17 (0.09) -0.05 (0.61) -0.01 (0.89) -0.03 (0.73) 
log2-
VEGFD 
-0.04 (0.68) 0 (0.96) 0.04 (0.69) -0.02 (0.88) 0.02 (0.86) 0.02 (0.81) 
log2-IL6 0.05 (0.61) 0.02 (0.85) 0.02 (0.88) 0.02 (0.84) 0.05 (0.66) -0.01 (0.89) 
log2-IL8 0.02 (0.87) 0.08 (0.41) 0.1 (0.31) 0.04 (0.69) 0.14 (0.13) 0.14 (0.14) 
log2-MCP1 0.19 (0.04) * 0.18 (0.07) 0.15 (0.11) 0.11 (0.24) 0.18 (0.06) 0.13 (0.17) 
log2-TNFa -0.07 (0.51) 0.05 (0.60) 0.02 (0.81) -0.05 (0.64) 0.08 (0.43) 0.06 (0.53) 












Table 6: Associations between sugar intake and systemic inflammatory and angiogenesis markers as measured by Spearman 
correlation, adjusted for age and gender and stratified by BMI(kg/m2) 














log2-CRP 0.00 (1.00) -0.06 (0.71) -0.03 (0.87) -0.05 (0.73) -0.10 (0.51) -0.10 (0.49) 
log2-SAA -0.13 (0.40) -0.15 (0.32) -0.15 (0.33) -0.03 (0.86) -0.05 (0.74) -0.08 (0.62) 
log2-SICAM -0.08 (0.57) -0.05 (0.73) -0.07 (0.62) -0.07 (0.65) -0.01 (0.96) -0.04 (0.78) 
log2-SVCAM -0.06 (0.70) -0.05 (0.71) -0.08 (0.57) -0.07 (0.61) -0.06 (0.68) -0.07 (0.65) 
log2-VEGFA -0.11 (0.43) -0.19 (0.15) -0.21 (0.12) 0.00 (1.00) -0.06 (0.68) -0.07 (0.60) 
log2-VEGFD -0.27 (0.04) * -0.35 (0.01) * -0.34 (0.01) * -0.13 (0.33) -0.23 (0.08) -0.23 (0.09) 
log2-IL6 -0.30 (0.04) * -0.33 (0.02) * -0.28 (0.05) * -0.11 (0.44) -0.11 (0.44) -0.11 (0.45) 
log2-IL8 -0.05 (0.72) -0.17 (0.20) -0.13 (0.35) 0.04 (0.78) -0.12 (0.36) -0.06 (0.66) 
log2-MCP1 -0.33 (0.01) * -0.44 (0.00) * -0.40 (0.00) * -0.32 (0.01) * -0.32 (0.01) * -0.32 (0.01) * 
















Table 6: Continued 














log2-CRP -0.01 (0.94) -0.07 (0.53) -0.13 (0.24) 0.20 (0.07) 0.13 (0.24) 0.03 (0.78) 
log2-SAA -0.14 (0.20) -0.05 (0.67) -0.05 (0.66) -0.10 (0.38) 0.02 (0.88) 0.00 (0.98) 
log2-SICAM -0.07 (0.50) -0.18 (0.09) -0.18 (0.09) 0.07 (0.50) -0.09 (0.42) -0.12 (0.26) 
log2-
SVCAM 
0.02 (0.85) 0.05 (0.65) 0.08 (0.47) 0.06 (0.56) 0.08 (0.47) 0.11 (0.29) 
log2-
VEGFA 
-0.19 (0.07) -0.14 (0.18) -0.15 (0.15) -0.05 (0.65) -0.01 (0.94) -0.04 (0.73) 
log2-
VEGFD 
-0.07 (0.52) -0.01 (0.90) 0.01 (0.91) -0.01 (0.91) 0.03 (0.78) 0.02 (0.83) 
log2-IL6 0.05 (0.62) 0.02 (0.86) 0.01 (0.91) 0.03 (0.78) 0.05 (0.61) -0.01 (0.92) 
log2-IL8 0.04 (0.68) 0.11 (0.25) 0.12 (0.24) 0.05 (0.61) 0.16 (0.10) 0.14 (0.14) 
log2-MCP1 0.19 (0.05) * 0.17 (0.07) 0.15 (0.13) 0.12 (0.22) 0.18 (0.06) 0.13 (0.17) 
log2-TNFa -0.04 (0.67) 0.08 (0.43) 0.04 (0.69) -0.03 (0.74) 0.10 (0.33) 0.07 (0.50) 









       In the first multiple linear regression, three markers presented as significant when viewing 
fructose, glucose, and sucrose as a percentage of total kcals, while adjusting for gender and 
age and stratifying by BMI(kg/m2).  In patients with a BMI < 25kg/m2, as all types of sugar 
increased, VEGFD levels decreased.  This trend also occurred with MCP1, yet only with 
fructose.  In those with a BMI ≥ 25kg/m2, as glucose and fructose intake increased, SVCAM 
levels increased as well [Table 7].   
       In the second multiple linear regression, which controlled for total kcals, in those with a 
BMI < 25kg/m2, as glucose and fructose increased, VEGFD levels decreased.  This negative 
trend did not occur with MCP1 in the model.  In those with a BMI ≥ 25kg/m2, as glucose and 
fructose intake increased, SVCAM levels increased as well [refer to Table 8].  Within this 























Table 7: Multiple linear regression analysis between sugar intake and systemic inflammatory and angiogenesis markers, 
adjusted for age and gender and stratified by BMI(kg/m2) 
Note, kcal/day equates to per 1000kcals of specified sugar per day 















log2-CRP 0.06 (0.98) 1.63 (0.70) 1.67 (0.68) -2.99 (0.68) -0.97 (0.95) -3.04 (0.84) 
log2-SAA -1.11 (0.40) -2.46 (0.43) -2.10 (0.48) -3.16 (0.55) -7.36 (0.50) -6.28 (0.57) 
log2-SICAM -0.37 (0.37) -0.59 (0.55) -0.55 (0.56) -0.65 (0.69) 0.36 (0.92) 0.21 (0.95) 
log2-SVCAM 0.12 (0.74) 0.28 (0.74) 0.31 (0.70) 0.42 (0.76) 0.73 (0.81) 0.81 (0.79) 
log2-VEGFA 0.33 (0.71) 0.16 (0.95) -0.13 (0.96) 1.46 (0.67) -2.44 (0.82) -2.62 (0.76) 
log2-VEGFD -1.34 (0.00) * -4.74 (0.00) * -3.80 (0.00) * -3.83 (0.05) * -13.85 (0.02) * -10.41 (0.03) * 
log2-IL6 -1.12 (0.41) -4.09 (0.17) -3.68 (0.20) -2.89 (0.60) -13.70 (0.19) -12.84 (0.22) 
log2-IL8 -0.42 (0.72) -3.42 (0.22) -2.88 (0.29) 2.12 (0.64) -9.73 (0.33) -7.77 (0.43) 
log2-MCP1 -1.17 (0.04) * -2.74 (0.05) * -3.01 (0.02) * -3.86 (0.08) -8.19 (0.09) -10.08 (0.04) * 














Table 7: Continued 
 















log2-CRP -0.14 (0.93) -0.94 (0.81) -2.64 (0.27) 7.82 (0.10) 8.32 (0.44) -2.53 (0.73) 
log2-SAA -2.41 (0.13) -4.69 (0.23) -2.86 (0.23) -3.30 (0.49) -7.79 (0.47) -5.33 (0.47) 
log2-SICAM -0.60 (0.21) -0.99 (0.40) -0.82 (0.26) -0.48 (0.73) -0.44 (0.89) -1.49 (0.50) 
log2-SVCAM -0.03 (0.94) 2.07 (0.05) 0.99 (0.13) 0.38 (0.77) 8.03 (0.01) * 4.14 (0.04) * 
log2-VEGFA -1.63 (0.12) -2.62 (0.24) -1.75 (0.35) -1.59 (0.61) -4.05 (0.51) -1.96 (0.73) 
log2-VEGFD -0.37 (0.46) 0.55 (0.60) 0.40 (0.65) -0.85 (0.56) 2.85 (0.33) 2.39 (0.36) 
log2-IL6 0.46 (0.68) 3.75 (0.10) 1.36 (0.39) -0.26 (0.94) 7.49 (0.26) 1.77 (0.72) 
log2-IL8 0.21 (0.89) 3.87 (0.23) 1.59 (0.47) 1.32 (0.77) 11.96 (0.19) 4.83 (0.48) 
log2-MCP1 0.59 (0.37) 1.46 (0.30) 0.67 (0.48) 2.07 (0.30) 3.84 (0.33) 1.82 (0.54) 
log2-TNFa -0.34 (0.51) 0.34 (0.75) 0.16 (0.82) -0.64 (0.69) 2.03 (0.50) 1.05 (0.64) 














Table 8: Multiple linear regression analysis between sugar intake and systemic inflammatory and angiogenesis markers, 
adjusted for age, gender, and total kcals and stratified by BMI(kg/m2) 
Note, kcal/day equates to per 1000kcals of specified sugar per day 
BMI < 25kg/m2 
Coefficient of regression (pvalue) Sucrose (kcal/day) Glucose (kcal/day) Fructose (kcal/day) 
log2-CRP -1.70 (0.55) 0.37 (0.95) 0.33 (0.95) 
log2-SAA 0.21 (0.92) -0.41 (0.92) 0.49 (0.90) 
log2-SICAM -0.30 (0.65) -0.20 (0.88) -0.10 (0.94) 
log2-SVCAM 0.47 (0.40) 0.67 (0.53) 0.86 (0.44) 
log2-VEGFA 1.41 (0.30) 1.47 (0.69) 0.82 (0.79) 
log2-VEGFD -1.26 (0.08) -4.55 (0.02) * -3.50 (0.04) * 
log2-IL6 -0.43 (0.84) -3.82 (0.31) -3.45 (0.37) 
log2-IL8 1.06 (0.56) -2.84 (0.43) -2.12 (0.56) 
log2-MCP1 -0.93 (0.30) -1.94 (0.26) -2.56 (0.15) 















Table 8: Continued 
BMI ≥ 25kg/m2 
Coefficient of regression (pvalue) Sucrose (kcal/day) Glucose (kcal/day) Fructose (kcal/day) 
log2-CRP 3.66 (0.06) 6.49 (0.16) 0.88 (0.75) 
log2-SAA -1.60 (0.43) -2.18 (0.65) -1.34 (0.64) 
log2-SICAM -0.12 (0.85) 0.31 (0.83) -0.13 (0.88) 
log2-SVCAM 0.19 (0.73) 3.57 (0.01) * 1.76 (0.03) * 
log2-VEGFA -1.04 (0.42) -1.27 (0.62) -0.28 (0.90) 
log2-VEGFD -0.24 (0.69) 1.20 (0.32) 1.08 (0.30) 
log2-IL6 0.03 (0.98) 4.11 (0.13) 1.17 (0.54) 
log2-IL8 0.27 (0.89) 5.11 (0.17) 2.15 (0.41) 
log2-MCP1 0.74 (0.38) 1.65 (0.31) 0.70 (0.54) 
log2-TNFa -0.55 (0.41) 0.48 (0.70) 0.24 (0.78) 










Table 9: Multiple linear regression analysis between sugar intake and systemic inflammatory and 
angiogenesis markers, adjusted for age, gender, total kcals, and T2DM and stratified by BMI(kg/m2) 
BMI < 25kg/m2 




-1.57 (0.56) 0.55 (0.91) 0.65 (0.90) 
log2-SAA -0.05 (0.98) -0.50 (0.89) 0.66 (0.86) 
log2-SICAM -0.40 (0.53) -0.40 (0.74) -0.42 (0.73) 
log2-SVCAM 0.18 (0.75) 0.08 (0.94) -0.16 (0.88) 
log2-VEGFA 0.42 (0.77) 0.29 (0.94) -0.46 (0.88) 
log2-VEGFD -1.11 (0.12) -3.23 (0.07) -2.38 (0.12) 
log2-IL6 0.07 (0.98) -3.43 (0.34) -2.71 (0.45) 
log2-IL8 0.53 (0.77) -3.57 (0.30) -3.35 (0.33) 
log2-MCP1 -0.77 (0.38) -1.49 (0.37) -1.95 (0.23) 













Table 9: Continued 
BMI ≥ 25kg/m2 
Coefficient of regression (pvalue) Sucrose (Kcal/day) Glucose (Kcal/day) Fructose 
(Kcal/day) 
log2-CRP 3.10 (0.10) 8.39 (0.10) 1.19 (0.67) 
log2-SAA -1.94 (0.34) -2.84 (0.61) -1.19 (0.70) 
log2-SICAM -0.59 (0.29) -1.56 (0.32) -0.47 (0.59) 
log2-SVCAM -0.17 (0.75) 1.50 (0.29) 1.00 (0.21) 
log2-VEGFA -1.21 (0.27) 0.34 (0.89) 0.50 (0.80) 
log2-VEGFD -0.84 (0.18) -0.61 (0.65) -0.20 (0.86) 
log2-IL6 -0.05 (0.97) 3.35 (0.31) -0.07 (0.98) 
log2-IL8 1.09 (0.54) 5.05 (0.18) 2.31 (0.36) 
log2-MCP1 0.86 (0.29) 2.83 (0.11) 0.90 (0.44) 















      To our knowledge, this is the first study to assess the association between sugar intake 
via a FFQ with systemic inflammation and angiogenesis biomarkers.  Overall, there was 
no association between sucrose, fructose, or glucose intake and systemic inflammatory and 
angiogenesis markers.  This result was contrary to our hypothesis.   
       In the context of previous research, our main finding fits into the varied picture of diet 
and CRC.  Zhu et al. found no association between high sugar consumption and disease-
free survival of CRC; however, the FFQ only assessed diet the year prior to diagnosis.41  
In contrast, Fung et al. found increased sugar-sweetened beverage intake to lower overall 
mortality among women with CRC.42   
      However, with BMI(kg/m2) stratification, associations between sugar intake and 
VEGFD, SVCAM, and MCP1 became apparent: those with a BMI < 25kg/m2 had lower 
VEGFD and MCP1 levels with higher sugar consumption.  Previous research by both 
Meyerhardt and Fuchs also found BMI to be an effect modifier; however, the study 
outcomes were sugar consumption and CRC recurrence, as compared to sugar intake and 
biomarkers in the current study.45, 46  In both the Meyerhardt and Fuchs studies, increased 
sugar consumption was associated with increased CRC recurrence, with increasing 
BMI(kg/m2) intensifying the effect.  However, most previous research suggests increased 






      Regarding VEGF, this biomarker has been found to be elevated in those with T2DM 
and obese individuals.68, 69  Within our cohort, only 17 patients had T2DM.  When stratified 
by BMI < 25kg/m2 and BMI ≥ 25kg/m2, 8% of patients with a BMI < 25kg/m2 had T2DM 
and 11% of patients with a BMI ≥ 25kg/m2 had T2DM.  This distribution seems unlikely 
to have skewed the results.   
     While VEGF is known as an angiogenesis marker, some research has associated 
increased VEGF levels with worsened CRC prognosis.6  We speculate that in patients with 
a BMI < 25kg/m2, increased sugar plays a protective role against cancer cachexia, which 
is associated with worsened CRC prognosis.  In contrast, in patients with a BMI ≥ 25kg/m2, 
increased sugar may act predominately to increase inflammation.   
      With regard to SVCAM, this biomarker is considered an indicator of CRC 
progression.70, 71  Given that increased sugar intake is associated with increased 
inflammation and increased inflammation is associated with worsened CRC prognosis, it 
follows that increased sugar consumption increased SVCAM levels in patients with a BMI 
≥ 25kg/m2.  Obesity is known to induce systemic inflammation; therefore, increased sugar 
intake may intensify this relationship.  This explanation may account for why this trend 
was not seen in patients with a BMI < 25kg/m2.   
 
 
4.1 Strengths and Limitations  
A major study strength is the novel correlation of FFQ data with blood plasma 
inflammatory and angiogenesis markers.  To note, many studies have assessed FFQ and 
cancer recurrence. However, to our knowledge, no previous study has assessed the 





assessed a set of ten different markers.  The association of FFQ data with blood plasma 
markers provides insight into the mechanism through which diet influences cancer 
progression.  A second strength of this study is the existence of multiple cohorts within the 
study, allowing the possibility to validate findings in another group of patients within 
ColoCare.  Lastly, the sample size is large, with adequate effect sizes for analyses.   
Regarding limitations, the FFQ methodology occurs random measurement errors; 
another limitation of FFQ methodology is recall bias.  However, the proposed FFQ was 
validated against two 24-hour dietary recalls.59  Despite the validity of the FFQ, there is 
potential for a change in diet after patient diagnosis.  To note, the FFQ used in this study 
does address whether there was a change in diet post-diagnosis. Therefore, we were able 
to account for reported dietary changes in the statistical analysis.  We recognize that other 
foods besides sugar can have pro-inflammatory properties.72  Further research could 
address the potential association between pro-inflammatory foods and blood plasma 











In summary, this study employed a novel approach of assessing the association of sugar 
intake patterns and their systemic inflammatory and angiogenesis markers in CRC patients.  
No association was found between sugar intake patterns and systemic inflammatory and 
angiogenesis markers.  Stratification of the data by BMI(kg/m2) did yield significant 
inverse correlations between sugar intake, as a percentage of total kcals, and VEGFD and 
MCP1 levels in those with a BMI < 25kg/m2 and a significant positive association between 
sugar intake and SVCAM in those with a BMI ≥ 25kg/m2, as measured by Pearson’s 
correlation. “Sugar feeds cancer” is a common phrase used among cancer patients, despite 
the lack of evidence for the statement.  This study helps to expand the scientific 
understanding of the role of diet in colorectal cancer patients.  Further research on 
evidence-based guidelines on dietary intake recommendations in colorectal cancer is 
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